Evaluation of p53peptide-pulsed Dendritic Cells in Combination With an Aromatase Inhibitor as a Treatment for Patients With Breast Cancer With Disease Recurrence After Adjuvant or First Line Endocrine Therapy.

Trial Profile

Evaluation of p53peptide-pulsed Dendritic Cells in Combination With an Aromatase Inhibitor as a Treatment for Patients With Breast Cancer With Disease Recurrence After Adjuvant or First Line Endocrine Therapy.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 27 Apr 2013

At a glance

  • Drugs Anastrozole (Primary) ; Cancer vaccine-p53 (Primary) ; Exemestane (Primary) ; Letrozole (Primary) ; Interleukin-2; Thymalfasin
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Jul 2012 SciClone Pharmaceuticals added as associations as reported in the European Clinical Trials Database record.
    • 30 May 2012 Planned end date changed from 1 Jul 2013 to 1 May 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top